Year All202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998 BioCryst to Present at Upcoming Investor Conferences May 07, 2024 Read More BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update May 06, 2024 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 Read More BioCryst to Report First Quarter 2024 Financial Results on May 6 Apr 22, 2024 Read More BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency Apr 17, 2024 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 03, 2024 Read More BioCryst to Present at Upcoming Investor Conferences Mar 25, 2024 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 05, 2024 Read More BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones Feb 26, 2024 Read More BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment Feb 23, 2024 Read More
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update May 06, 2024 Read More
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency Apr 17, 2024 Read More
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones Feb 26, 2024 Read More
BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment Feb 23, 2024 Read More